Anaemia is common in chronic kidney disease (CKD) encompassing non-dialysis dependent CKD (NDD-CKD) and dialysis dependent CKD (DD-CKD); people on peritoneal dialysis (PD) and haemodialysis (HD); and kidney transplant recipients (KTR). Iron deficiency and erythropoieTn deficiency (a consequence of impaired oxygen sensing by the failing kidneys) are perhaps the most common causes of anaemia in people with CKD, especially those requiring kidney replacement therapy (KRT/dialysis). The Renal NaTonal Service Framework and NaTonal InsTtute for Health and Clinical Excellence in the UK, and Kidney Disease Improving Global Outcomes (KDIGO), all advocate treatment of anaemia in people with CKD. Blood transfusions are infrequently required, and newer therapies such as Hypoxia-Inducible Factor (HIF-PHI) stabilisers are now in current use. Anaemia is a major clinical problem in people suffering from CKD. This guideline adds to the previous 2017 and updated 2020 anaemia guidelines.

贫血在慢性肾脏疾病（CKD）中很常见，包括非透析依赖性CKD（NDD-CKD）和透析依赖性CKD (DD-CKD)；腹膜透析（PD）和血液透析（HD）患者；肾脏移植受者（KTR）。铁缺乏和促红细胞生成素缺乏（肾功能衰竭的氧感知受损的结果）可能是CKD患者贫血最常见的原因，特别是那些需要肾脏替代治疗（KRT/透析）的患者。英国国家肾脏服务框架和国家健康与临床卓越研究所以及肾脏疾病改善全球结果（KDIGO）都提倡对CKD患者进行贫血治疗。输血是不经常需要的，新的治疗方法，如低氧诱导因子（HIF-PHI）稳定剂现在正在使用。贫血是慢性肾病患者的主要临床问题。本指南是对先前的2017年和更新的2020年贫血指南的补充。